

# Jan Mares

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9460537/publications.pdf>

Version: 2024-02-01

38  
papers

1,364  
citations

471371

17  
h-index

360920

35  
g-index

39  
all docs

39  
docs citations

39  
times ranked

2185  
citing authors

#	ARTICLE	IF	CITATIONS
1	Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. <i>Neurotherapeutics</i> , 2022, 19, 753-773.	2.1	14
2	Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk. <i>Neurotherapeutics</i> , 2021, 18, 1654-1656.	2.1	1
3	Targeting B Cells to Modify MS, NMOSD, and MOGAD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	37
4	Targeting B cells to modify MS, NMOSD, and MOGAD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	30
5	Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 944.	1.1	0
6	Changes in oxygen saturation and the retinal nerve fibre layer in patients with optic neuritis associated with multiple sclerosis in a 6-month follow-up. <i>Acta Ophthalmologica</i> , 2020, 98, 841-847.	0.6	5
7	Alemtuzumab: Rare serious adverse events of a high-efficacy drug. <i>Multiple Sclerosis Journal</i> , 2020, 26, 737-740.	1.4	14
8	Drug Treatment of Clinically Isolated Syndrome. <i>CNS Drugs</i> , 2019, 33, 659-676.	2.7	12
9	Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. <i>Current Opinion in Neurology</i> , 2019, 32, 365-377.	1.8	73
10	Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 – continuity and change. <i>Current Opinion in Neurology</i> , 2019, 32, 327-337.	1.8	32
11	Recommendations for cerebrospinal fluid analysis. <i>Folia Microbiologica</i> , 2019, 64, 443-452.	1.1	8
12	Managing Risks with Immune Therapies in Multiple Sclerosis. <i>Drug Safety</i> , 2019, 42, 633-647.	1.4	18
13	Changes in oxygen saturation and the retinal nerve fibre layer in patients with optic neuritis – a pilot study. <i>Acta Ophthalmologica</i> , 2018, 96, e309-e314.	0.6	12
14	Cerebrospinal fluid levels of chromogranin A and phosphorylated neurofilament heavy chain are elevated in amyotrophic lateral sclerosis. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 360-364.	1.0	14
15	Cerebrospinal fluid and serum levels of interleukin-8 in patients with multiple sclerosis and its correlation with Q-albumin. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 14, 12-15.	0.9	22
16	T- lymphocytes and B-lymphocytes and their role in multiple sclerosis. <i>Neurologie Pro Praxi</i> , 2017, 18, 318-321.	0.0	0
17	Clusterin CSF levels in differential diagnosis of neurodegenerative disorders. <i>Journal of the Neurological Sciences</i> , 2016, 361, 117-121.	0.3	26
18	Stable isotope dilution ultra-high performance liquid chromatography–tandem mass spectrometry quantitative profiling of tryptophan-related neuroactive substances in human serum and cerebrospinal fluid. <i>Journal of Chromatography A</i> , 2016, 1437, 145-157.	1.8	43

#	ARTICLE	IF	CITATIONS
19	Long-term safety and efficacy of teriflunomide. <i>Neurology</i> , 2016, 86, 920-930.	1.5	108
20	Orthostatic hypotension is associated with decreased cerebrospinal fluid levels of chromogranin A in early stage of Parkinson disease. <i>Clinical Autonomic Research</i> , 2015, 25, 339-342.	1.4	4
21	Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: a pilot study. <i>Journal of Neural Transmission</i> , 2015, 122, 273-277.	1.4	23
22	Thalamic atrophy and cognitive impairment in clinically isolated syndrome and multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2014, 342, 62-68.	0.3	40
23	Tau protein, beta-amyloid1 $\beta$ 42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. <i>Journal of the Neurological Sciences</i> , 2014, 343, 120-124.	0.3	58
24	Intrathecal synthesis in particular types of multiple sclerosis. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2014, 158, 124-126.	0.2	7
25	A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2013, 260, 984-997.	1.8	205
26	Recommendations for the Use of Prolonged $\beta$ Release Fampridine in Patients with Multiple Sclerosis (<sc>MS</sc>). <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 302-306.	1.9	11
27	Tau protein and beta-amyloid1-42 CSF levels in different phenotypes of Parkinson $\beta$ s disease. <i>Journal of Neural Transmission</i> , 2012, 119, 353-362.	1.4	25
28	Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome. <i>Neurological Research</i> , 2011, 33, 415-420.	0.6	31
29	A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup> $\beta$ </sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. <i>European Journal of Neurology</i> , 2011, 18, 1122-1131.	1.7	364
30	CSF markers of neurodegeneration in Parkinson $\beta$ s disease. <i>Journal of Neural Transmission</i> , 2010, 117, 1177-1181.	1.4	57
31	New laboratory markers in diagnosis of alzheimer dementia. <i>Neurological Research</i> , 2009, 31, 1056-1059.	0.6	10
32	The assessment of beta amyloid, tau protein and cystatin C in the cerebrospinal fluid: laboratory markers of neurodegenerative diseases. <i>Neurological Sciences</i> , 2009, 30, 1-7.	0.9	13
33	CORRELATION OF THE ICG INDEX AND OLIGOCLONAL BANDS IN THE CEREBROSPINAL FLUID OF PATIENTS WITH MULTIPLE SCLEROSIS. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2008, 152, 247-249.	0.2	17
34	Applications of new laboratory marker assays in neurological diagnoses - A pilot study. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2005, 149, 265-266.	0.2	3
35	Applications of new laboratory marker assays in neurological diagnoses - a pilot study. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2005, 149, 265-6.	0.2	2
36	USE OF CYSTATIN C DETERMINATION IN CLINICAL DIAGNOSTICS. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2003, 147, 177-180.	0.2	17

#	ARTICLE	IF	CITATIONS
37	Use of cystatin C determination in clinical diagnostics. Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia, 2003, 147, 177-80.	0.2	7
38	Correlation between retinal oxygen saturation and the haemodynamic parameters of the ophthalmic artery in healthy subjects. Acta Ophthalmologica, 0, , .	0.6	1